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Bridging to transplantability with a ventricular assist device
E. V. Potapov, MD, Y. Weng, MD, PhD, M. Jurmann, MD, H. Lehmkuhl, MD, and R. Hetzer, MD, PhD, Berlin, Germany
The implantation of a ventricular assist device (VAD) isan accepted option in patients with end-stage heartfailure. However, the durability of these devices islimited to a number of years, and complications still
limit outcome. In children and young adults with end-stage heart
failure and contraindications for heart transplantation, there are
thus no long-term options available.
Clinical Summary
A 15-year-old girl had osteosarcoma of the left femur, which was
radically operated on in December 2001. The patient received
postoperative chemotherapy with doxorubicin and cisplatin for 5
months. In May 2002, cardiomyopathy developed, subsequently
leading to biventricular heart failure. The patient’s condition de-
teriorated rapidly, with lung edema and signs of multiorgan dys-
function necessitating inotropic support and ventilation. In June
2002, the patient was transferred from the Netherlands to Berlin
and immediately supported with an extracorporeal biventricular
assist device (Berlin Heart, Berlin, Germany). The postoperative
course was uneventful. One month later, spongioplasty restored
the integrity and mechanical function of the femur. The girl was
discharged home in September 2002 and went back to school. In
June 2003, 1 year and 7 months after tumor removal, a computed
tomographic scan showed no evidence of tumor recurrence or
metastatic processes. The patient was listed for heart transplanta-
tion and received a donor heart after 420 days on support, 10 days
after her 17th birthday. Again, the postoperative course was un-
eventful. Almost 2 years after heart transplantation, despite triple
immunosuppression protocol, the malignancy remains in remis-
sion.
Discussion
A few cases have been reported of urgent heart transplantation
after treatment of osteosarcoma (for example, at 16 months,1 2
years and 5 months,2 and 10 years3) because of slow progression
of chemotherapy-induced cardiomyopathy. In our case of rapid
deterioration, however, VAD implantation was the only means of
saving the patient’s life and gaining time. This case opens up new
horizons for VAD implantation as a “bridge to transplantability”
for patients with contraindications for heart transplantation, in
addition to the established indications of direct bridging to heart
transplantation or myocardial recovery or as a definitive therapy.
In some patients with fixed pulmonary hypertension precluding
heart transplantation, long-term support with a left VAD leads to
a significant and sustained decrease in pulmonary vascular resis-
tance, allowing successful heart transplantation after 3 to 6 months
with the left VAD.4 During long-term support with a VAD, infec-
tive, thromboembolic, or bleeding complications may arise; it is
therefore an individual decision as to how long the patient should
be mechanically supported before the necessary freedom from
tumor recurrence can be postulated. In this case, freedom from
tumor for 1 year and 7 months allowed heart transplantation to be
performed with subsequent immunosuppression and without tumor
recurrence to date, 1 year and 9 months later. Despite the prom-
ising long-term prognosis,1,3,5 close posttransplantation follow-up
focusing on tumor recurrence will remain necessary. In our case,
long-term VAD support allowed the patient to be listed for heart
transplantation after she had reached a status of transplantability.
In such cases, as well as for patients with elevated pulmonary
vascular resistance, bridge to transplantability may represent a new
concept for long-term VAD support.
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